Clinical Research Directory
Browse clinical research sites, groups, and studies.
3 clinical studies listed.
Filters:
Tundra lists 3 Recurrent Nasopharynx Carcinoma clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.
This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.
NCT03074513
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
This phase II trial studies how well atezolizumab and bevacizumab work in treating patients with rare solid tumors. Immunotherapy with monoclonal antibodies, such as atezolizumab and bevacizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Gender: All
Ages: 18 Years - Any
Updated: 2026-03-11
1 state
NCT07332247
PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Selective Re-irradiation for Locally Advanced Recurrent NPC
This phase II randomized trial evaluates PD-1 inhibitor plus chemotherapy followed by immediate versus selective re-irradiation in locally advanced recurrent nasopharyngeal carcinoma. The study aims to determine whether sequential radiotherapy provides additional survival benefit beyond systemic immunochemotherapy.
Gender: All
Ages: 18 Years - 70 Years
Updated: 2026-02-04
1 state
NCT06802835
EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma
This is a prospective, single-arm, phase II clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of EGFR antibody combined with programmed death 1 (PD-1) antibody and chemotherapy in recurrent/metastatic nasopharyngeal carcinoma patients.
Gender: All
Ages: 18 Years - 75 Years
Updated: 2025-05-16
1 state